ClinicalTrials.gg
Sign In
CompletedNCT03971279Updated Nov 26, 2019

Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis

An observational study in Posterior Uveitis, sponsored by Benha University. Completed at 1 site in United Arab Emirates. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-26.

Sponsored by Benha University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16
Ages
18 Years and older
Sex
All
01

Study summary

VKH disease is a vision threatening condition.The investigators consider that ozurdex intravitreal implant is an effective line of treatment in recurrent VKH posterior uveitis.

Read the detailed description

Baseline ,and postoperative 1 ,6 ,12 and 24 months full ophthalmic examination was done.

Procedure included intravitreal injection of Dexamethasone implant 0.7 mg (Ozurdex(®); Allergan, Inc, Irvine, CA)

02

Conditions studied

  • Posterior Uveitis

Browse trials for

Keywords

  • dexamethasone;VKH
03

In context

Uveitis, Posterior

61 studies on the registry are indexed under Uveitis, Posterior; 4 are open to participants now.

This study's enrollment of 16 is below the median of 42 across 10 observational studies indexed under Uveitis, Posterior.

Browse Uveitis, Posterior studies →

Lead sponsor

Benha University is the lead sponsor of 362 studies on the registry; 66 are open to participants now.

Browse Benha University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

16 patient with VKH disease who have recurrent attacks of posterio uveitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recurrent VKH posterior uveitis

Exclusion criteria

Exclusion Criteria:

  • retinal pathology, other causes of posterior uveitis
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16 participants (actual)
Patient registry
No

Interventions

06

What researchers measure

Primary outcomes

  1. Best corrected visual acuity (BCVA)

    Change in BCVA

    Time frame: 2 years

Secondary outcomes

  1. optical coherence tomography (OCT) foveal thickness

    changes in central foveal thickness

    Time frame: 2 years

07

Study locations

1 site
  • INMC
    Abu Dhabi, United Arab Emirates
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Nov 2019, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2019
First posted
Jun 3, 2019
StartActual
Jan 1, 2017
Primary completionActual
Nov 22, 2019
CompletionActual
Nov 22, 2019
Last update
Nov 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03971279
Lead sponsor
Benha University
Responsible party
Tarek Roshdy mohamed Mahgoub ELhamaky (Lecturer of ophthalmology, Benha University) — Principal investigator
First posted
Jun 3, 2019
Start date
Jan 1, 2017
Primary completion
Nov 22, 2019
Completion
Nov 22, 2019
Last update
Nov 26, 2019

Study contacts

Tarek Elhamaky
principal investigator · Benha university faculty of medicine , INMC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Uveitis, Posterior →

Other studies from this sponsor

Benha University →

Start the discussion